Citius Pharmaceuticals Inc Stock Price, News & Analysis

Citius Pharmaceuticals (Nasdaq: CTXR) provided updates on its Mino-Lok^® Phase 3 trial during a recent webinar, highlighting the growing interest from the clinical community. Mino-Lok is an antibiotic lock therapy aimed at salvaging central venous catheters (CVCs) in patients with catheter-related bloodstream infections (CRBSIs). Currently, no FDA-approved therapies exist for this purpose. The company believes that Mino-Lok could set a new standard in treating CRBSIs, emphasizing its potential to penetrate biofilms and maintain CVC access. The FDA has granted Mino-Lok Fast Track designation.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced that its President and CEO, Myron Holubiak, participated in a Benzinga interview discussing the company's product pipeline, Covid-19 impact, and future milestones. The company focuses on critical care products, particularly in anti-infective treatments and stem cell therapy. Notably, its lead product, Mino-Lok®, is in a Phase III trial and has received Fast Track designation by the FDA. The interview is available on the Citius corporate website.

Citius Pharmaceuticals will participate in the Benzinga Biotech Small Cap Conference on March 24-25, 2021, where Executive Chairman Leonard Mazur will discuss the Phase 3 trial of Mino-Lok®, an antibiotic solution for catheter-related bloodstream infections. The trial is progressing as planned, with full enrollment expected this year. The U.S. market opportunity for Mino-Lok® is projected at $750 million, with a worldwide potential of $1.5 billion. Investors can register for the conference via the provided event website.

Citius Pharmaceuticals (Nasdaq: CTXR) will present at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. CEO Myron Holubiak will provide updates on the company's product pipeline, including Mino-Lok, which is in Phase 3 trials. The presentation will be accessible via webcast starting March 9 at 7:00 a.m. ET, with a replay available for 90 days. The company recently issued its February 2021 Letter to Shareholders, detailing business and clinical developments. For more information, visit the company's website.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) has successfully completed a registered direct offering, raising approximately $76.5 million through the sale of 50,830,566 shares of common stock and warrants to purchase 25,415,283 shares. The offering was priced at $1.505 per share, with warrants exercisable at $1.70, valid for five years. Proceeds will support pre-clinical and clinical development, along with working capital needs. H.C. Wainwright & Co. served as the exclusive placement agent. The securities were registered under an effective SEC filing.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) has announced a registered direct offering to sell 50,830,566 shares of common stock at $1.505 per share, along with warrants for an additional 25,415,283 shares at an exercise price of $1.70. The offering is expected to close around February 19, 2021, with gross proceeds of approximately $76.5 million. Funds will be used for general corporate purposes, including clinical development of product candidates. H.C. Wainwright & Co. is the exclusive placement agent for this offering.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) released a shareholder letter detailing its recent achievements and plans for 2021. Key updates include expected interim analysis from the Mino-Lok® pivotal trial and filing of the Halo-Lido IND and Phase 2b protocol in Q2. The company is also progressing with Mino-Wrap™ and its NoveCite i-MSCs program. A recent private placement raised $20 million, and warrant exercises generated an additional $4.5 million. These developments reflect Citius's commitment to advancing its clinical programs, aiming for significant milestones this year.

Citius Pharmaceuticals (Nasdaq: CTXR) will present at the Virtual Investor Conferences Small and Microcap Showcase on February 4, 2021, at 1:00 p.m. ET. Chairman Leonard Mazur will provide updates on the lead candidate MinoLok, currently in Phase 3 trials, as well as three other active programs. The event is interactive, allowing real-time questions from investors. An archived version will be available post-event. Pre-registration is recommended for participation.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) has completed a private placement, raising approximately $20.0 million by issuing 15,455,960 shares of common stock priced at $1.294 per share, along with warrants for an additional 7,727,980 shares. The associated warrants have an exercise price of $1.231 and are valid for five and a half years. Proceeds will support general corporate purposes, including pre-clinical and clinical development. The company has obligations to file a registration statement with the SEC to facilitate resale of the shares.